European venture funding for life science sector
European venture funding into life sciences is set to top $2bn investment, reinforcing the health of an early-stage ecosystem.
The UK continues to take the largest share of venture funding at $1.2bn since the beginning of 2016. New funds like the Oxford Sciences Innovation and Syncona will likely reinforce this over the next few years.
The greater risk is the lowering of the quality bar as marginal companies obtain investment and this could adversely impact the exit environment.
Two major UK venture groups are engaged in a potential merger, with IP Group and Touchstone Innovations both publicly listed investment vehicles focused on university spin-outs.
Read the full story here